Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 6/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 3/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16735358 | 0.91 | MAPT (0.64) | RAB9AMAPTLMNANPC1MAPK1 | |
| SCHEMBL29227478 | 0.91 | MEN1 (0.62) | RAB9AMAPTLMNAMEN1HTT | |
| SCHEMBL30822365 | 0.91 | MEN1 (0.62) | RAB9AMAPTLMNAMEN1HTT | |
| SCHEMBL1358751 | 0.89 | MAPT (0.70) | RAB9AMAPTLMNANPC1MAPK1 | |
| SCHEMBL1454929 | 0.88 | LMNA (0.53) | RAB9AMAPTLMNANPC1MAPK1 | |
| SCHEMBL31524108 | 0.88 | MAPT (0.79) | RAB9AMAPTLMNANPC1MAPK1 | |
| SCHEMBL28787844 | 0.87 | MAPT (0.67) | RAB9AMAPTLMNANPC1MAPK1 | |
| SCHEMBL811365 | 0.87 | MAPT (0.60) | RAB9AMAPTLMNAMAPK1MEN1 | |
| SCHEMBL2494880 | 0.86 | MEN1 (0.62) | RAB9AMAPTLMNANPC1MAPK1 | |
| SCHEMBL22025453 | 0.86 | MAPT (0.70) | RAB9AMAPTLMNANPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101068805-A | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2007-11-07 | — | — | CN | claimed |
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | claimed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| US-20250152593-A1 | p38 MAPK INHIBITORS AND USES THEREOF | HOPE CITY (US) | 2025-05-15 | — | — | US | disclosed |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
| WO-2018208132-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-11-15 | — | — | WO | disclosed |
| EP-2350083-B1 | PYRIMIDO[5,4-D]PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016165205-A1 | NOVEL BCR-ABL KINASE INHIBITOR | 中国科学院合肥物质科学研究院 | 2016-10-20 | — | — | WO | disclosed |
| CN-1321150-A | Amide derivs. useful as inhibitors of production of cytokines | ASTRAZENECA AB (SE) | 2001-11-07 | — | — | CN | disclosed |
| CN-1300278-A | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2001-06-20 | — | — | CN | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| CN-1271279-A | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LTD (GB) | 2000-10-25 | — | — | CN | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | RAB9A 2165/4885MAPT 1242/4885LMNA 4178/4885 |
| US-20250152593-A1 | p38 MAPK INHIBITORS AND USES THEREOF | MAPK8, MAPK1, MAPK7 | RAB9A 1147/4885MAPT 1363/4885LMNA 2960/4885 |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | RAB9A 1432/4885MAPT 2459/4885LMNA 3498/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | RAB9A 1432/4885MAPT 2459/4885LMNA 3498/4885 |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | BTK, SYK, LCK | RAB9A 2165/4885MAPT 1242/4885LMNA 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.